相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Liver ChREBP Protects Against Fructose-Induced Glycogenic Hepatotoxicity by Regulating L-Type Pyruvate Kinase
Jian-Hui Shi et al.
DIABETES (2020)
Metformin lowers glucose 6-phosphate in hepatocytes by activation of glycolysis downstream of glucose phosphorylation
Tabassum Moonira et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective
Loranne Agius et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Cellular acidosis triggers human MondoA transcriptional activity by driving mitochondrial ATP production
Blake R. Wilde et al.
ELIFE (2019)
Low metformin causes a more oxidized mitochondrial NADH/NAD redox state in hepatocytes and inhibits gluconeogenesis by a redox-independent mechanism
Ahmed Alshawi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
α-cell glucokinase suppresses glucose-regulated glucagon secretion
Davide Basco et al.
NATURE COMMUNICATIONS (2018)
Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity
Deqiang Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models
Yoshinori Tsumura et al.
PLOS ONE (2017)
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes
Ziad H. Al-Oanzi et al.
DIABETES OBESITY & METABOLISM (2017)
Dietary carbohydrate and control of hepatic gene expression: mechanistic links from ATP and phosphate ester homeostasis to the carbohydrate-response element-binding protein
Loranne Agius
PROCEEDINGS OF THE NUTRITION SOCIETY (2016)
Hormonal and Metabolite Regulation of Hepatic Glucokinase
Loranne Agius
ANNUAL REVIEW OF NUTRITION, VOL 36 (2016)
ChREBP regulates fructose-induced glucose production independently of insulin signaling
Mi-Sung Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Genome-Wide Analysis of ChREBP Binding Sites on Male Mouse Liver and White Adipose Chromatin
Naravat Poungvarin et al.
ENDOCRINOLOGY (2015)
Modulation of Glucokinase Regulatory Protein: A Double-Edged Sword?
Martijn C. G. J. Brouwers et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Present status of clinical deployment of glucokinase activators
Akinobu Nakamura et al.
JOURNAL OF DIABETES INVESTIGATION (2015)
Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes
D. J. Baker et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
A patent review of glucokinase activators and disruptors of the glucokinase - glucokinase regulatory protein interaction: 2011-2014
Kevin J. Filipski et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Lessons from glucokinase activators: the problem of declining efficacy
Loranne Agius
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats
Derek M. Erion et al.
PLOS ONE (2014)
Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans
Frederic De Ceuninck et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice
Frederic De Ceuninck et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus
A. Kiyosue et al.
DIABETES OBESITY & METABOLISM (2013)
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2013)
Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice
Nirav Dhanesha et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?
Franz M. Matschinsky
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes
Catherine Arden et al.
BIOCHEMICAL JOURNAL (2012)
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus
L. A. Morrow et al.
DIABETES OBESITY & METABOLISM (2012)
Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat
M. Futamura et al.
DIABETOLOGIA (2012)
Glucokinase Activators AZD6370 and AZD1656 Do Not Affect the Central Counterregulatory Response to Hypoglycemia in Healthy Males
Ensio Norjavaara et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus
Jeffrey A. Pfefferkorn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery of Piragliatin-First Glucokinase Activator Studied in Type 2 Diabetic Patients
Ramakanth Sarabu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Property based optimisation of glucokinase activators - discovery of the phase IIb clinical candidate AZD1656
Michael J. Waring et al.
MEDCHEMCOMM (2012)
Elevated Glucose Represses Liver Glucokinase and Induces Its Regulatory Protein to Safeguard Hepatic Phosphate Homeostasis
Catherine Arden et al.
DIABETES (2011)
Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
Gary E. Meininger et al.
DIABETES CARE (2011)
Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice
Maria Sorhede Winzell et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Novel glucokinase activators: a patent review (2008-2010)
Ramakanth Sarabu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2011)
Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs
Jun-ichi Eiki et al.
MOLECULAR PHARMACOLOGY (2011)
Impact of Small-Molecule Glucokinase Activator on Glucose Metabolism and β-Cell Mass
Akinobu Nakamura et al.
ENDOCRINOLOGY (2009)
Carbohydrate-response element-binding protein deletion alters substrate utilization producing an energy-deficient liver
Shawn C. Burgess et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
ChREBP•Mlx is the principal mediator of glucose-induced gene expression in the liver
Lin Ma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators
KJ Brocklehurst et al.
DIABETES (2004)
分享论文
